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The cellular E3 ubiquitin ligase E6AP (UBE3A) interacts with the cancer-associated HPV E6 oncoproteins, where together with the viral E6
oncoprotein it binds and targets the degradation of the p53 tumor suppressor. We find that the HPV-11E6 protein also associates with E6AP in
vivo, and thereby can target the degradation of an E6-associated protein. Mutation of an E6-binding LXXLL peptide motif on E6AP eliminated the
association, revealing a common mode of interaction between high- and low-risk E6 proteins and E6AP. E6AP was required for the in vivo
degradation of DLG1 by both HVP-18 E6 and a chimeric HPV-11E6. The common functional interaction of both cancer-associated and non-
cancer-associated E6 proteins with E6AP establishes a common mechanism for E6 proteins trophic to mucosal squamous epithelium.
© 2006 Elsevier Inc. All rights reserved.Keywords: Ubiquitin; Proteasome; Cervical cancer; Respiratory papillomatosis; RRP; Genital wartsIntroduction
Papillomaviruses are causative agents of benign tumors of
cutaneous and mucosal squamous epithelia. A subset of
papillomaviruses induce mucosal epithelial tumors that may
develop into epithelial malignancies; these types are termed
“high-risk” HPV types (prototypes are HPV-16, 18, and 31).
Conversely, HPV types that produce only benign mucosal
epithelial papillomas are termed “low-risk” types (typified by
HPV types 6 and 11) (reviewed in Munger et al., 2004).
However, low-risk papillomaviruses can produce debilitating
benign anogenital or respiratory tumors, accounting for their
medical importance (Sinal and Woods, 2005). While consider-
able effort has established a diverse set of functions for high-risk
E6 proteins, little is known about the functions of the low-risk
E6 proteins. However, HPV-11E6 (11E6) is essential for
maintenance of the viral DNA at normal copy numbers, and a
set of mutants in E6 which results in reduced episomal copy
number has been described (Oh et al., 2004).
E6 oncoproteins are small zinc finger proteins that fold to
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oncoproteins and E6 from bovine papillomavirus (BE6) interact
with cellular proteins by binding to an 8 amino acid peptide
displayed on the target protein (XLXXLLXX, abbreviated
LXXLL here, with limited substitution of leucine by other
hydrophobic amino acids) (Chen et al., 1998; Elston et al.,
1998; Vande Pol et al., 1998); this interaction is required for
cellular transformation by BE6 (Bohl et al., 2000; Vande Pol et
al., 1998). HPV-16 E6 (16E6) interacts with a LXXLL peptide
sequence found on the cellular E3 ubiquitin ligase E6AP
(termed LQELL in E6AP), and together with E6AP binds to the
p53 tumor suppressor protein resulting in ubiquitin-mediated
degradation of p53 by the proteosome (Huibregtse et al., 1991,
1993a, 1993b; Werness et al., 1990). The efficient in vivo
degradation of p53 by high-risk E6 requires both E6AP and the
E3 ubiquitin ligase activity of E6AP (Cooper et al., 2003), and
LXXLL peptides can compete the degradation of p53 in vitro
and in vivo (Sterlinko Grm et al., 2004). High-risk E6 proteins
also target the degradation of other cellular proteins, particularly
cellular PDZ proteins. These PDZ proteins bind the carboxy
terminal five amino acids of high-risk E6 proteins that is a
ligand for PDZ domains (Kiyono et al., 1997; Lee et al., 1997).
While the cellular PDZ protein scribble has been found to
associate with E6AP together with E6 (Nakagawa and
Fig. 1. 11E6 interacts with E6AP in a yeast two-hybrid assay. E6AP fusions to
the B42 transactivator expressed in the strain YPH500 were introduced by
mating to the lexA responsive lacZ and His3 reporter strain TAT7 containing
either LexA or LexA fused to 11E6 or 16E6 as previously described (Cooper et
al., 2003; Vande Pol et al., 1998). Diploid yeast was selected on glucose plates
by auxotrophic markers and then patched to galactose-XGAL plates to induce
expression of the B42 transactivator prey fusion proteins. (A) 11E6 binds the
same region of E6AP as 16E6. B42 transactivator domain fusions to E6AP,
E6AP-C843A (mutated in ubiquitin ligase activity), and E6AP-C843A further
mutated in the 16E6-binding site (aa 409-LQELL-413) LQELS or LQEAS are
indicated. E6AP-C843A-ΔE6 contains an in-frame deletion of amino acids
391–408 deleting the entire E6-binding site. Galactose-XGAL plates test for
interaction with the indicated lexA fusions with blue color indicating in vivo
interaction. (B) Interaction of 16E6 but not 11E6 with the isolated E6-binding
site of E6AP-C843A. The peptides ELTLQELLGEERR (termed LQELL
peptide) or ELTLQELSGEERR (termed LQELS) fused to the HA epitope and
the B42 transactivator were tested on Galactose XGAL plates for two-hybrid
interaction with the indicated LexA fusions.
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E6AP does not play a role in the degradation of the DLG1 PDZ
domain protein by 18E6 (Pim et al., 2000), but as yet anFig. 2. Association of 11E6 and 16E6 with E6AP in mammalian cells. (A) Immune pr
plasmids were transiently overexpressed in CV-1 cells by vaccinia pTM1 transfec
immunoblot with the indicated antibodies or immune precipitated with antibodies dire
2003). Black vertical lines group samples transfected with either FLAG vector, FLAG
position of a lane excised from the figure. (B) Immune precipitation of E6AP co-pr
samples transfected with either FLAG vector, FLAG-16E6, or FLAG-11E6. (C) Red
plasmids were co-expressed in CV-1 cells as in parts A and B with a constant am
normalized samples from NP40 lysed cells were probed with antibodies first for the E
and finally FLAG-E6. (D) 11E6 mutants defective for HPV-11 plasmid maintenance
EE-E6AP-C843A (mutated in ubiquitin ligase activity) were co-transfected with 11E6
zinc-binding motif, L111Q andW133R are in conserved buried residues and R78Awa
al., 2006). Cells transfected with EE-E6AP were harvested in SDS lysis buffer and an
C843A were lysed in NP40 lysis buffer and protein content equalized, with a porti
remainder immune precipitated with antibody to FLAG. Immunoblots were perform
stably expressed in C33A cells. C33A cells were retrovirally transduced with 2X-FLA
protein equalized NP40 lysates from 6×107 pooled drug resistant cells 10 passages af
of FLAG-E6 (top panel), tubulin (second panel) and E6AP (third panel from top). T
FLAG epitope and washed precipitates were analyzed for the expression of FLAG-Ealternative ubiquitin ligase has not been identified. How the
low-risk E6 proteins interact with cellular proteins has not been
defined, and binding of low-risk E6 proteins to LXXLL
peptides has not been demonstrated (Zanier et al., 2005).
However, low-risk E6, like high-risk E6, has the ability to target
the degradation of proteins in vitro, as fusion of a PDZ ligand to
the carboxy terminus of HPV-11E6 (11E6) confers upon 11E6
the ability to degrade DLG1 in vitro, similar to high-risk 18E6
(Pim et al., 2002). But the ubiquitin ligase by which 11E6 might
target proteins for degradation has not been identified.
Results
We noted that E6AP interacted with both 11E6 and 16E6 in
yeast two-hybrid assays if the ubiquitin ligase activity of E6AP
was inactivated by mutation (in Fig. 1A, E6AP-C843A is
mutated in ubiquitin ligase activity). We have previously shown
that co-expression of E6 and wild-type E6AP in this yeast
system results in loss of detectable E6AP protein while the
expression of the ubiquitin-ligase defective E6AP-C843A is
retained (Cooper et al., 2003). In the context of the full E6AP
protein, 16E6 interacted with both E6AP-C843A containing the
intact LQELL motif and the E6AP-C843A-LS point mutant
(LQELL mutated to LQELS), but not doubly mutant E6AP-
C843A-AS (LQELLmutated to LQEAS)-binding site (Fig. 1A).
When the E6-binding site of E6AP was displayed as isolated
peptides fused to a transactivator, 16E6 would only interact with
LQELL but not LQELS (Fig. 1B). 11E6was more selective in its
interaction with E6AP, interacting well with E6AP-C843A
(LQELL), weakly with E6AP-C843A-LQELS but not with
E6AP-C843A-LQEAS (Fig. 1A). But unlike 16E6, 11E6 did not
detectably interact with LQELL or LQELS displayed as peptides
outside the context of the full E6AP-C843A protein (Fig. 1B).
To confirm the yeast two-hybrid interactions, E6AP, 16E6
and 11E6 were co-expressed in vivo, immunoprecipitated with
antibodies directed to the E6 epitope tags, and analyzed by
immunoblot. 11E6 and 16E6 each associated with E6AP by co-
immunoprecipitation (Fig. 2A). Reciprocal co-immune precip-
itation using the EE epitope tag on E6AP gave the same result
(Fig. 2B). Mutation of the ubiquitin ligase activity of E6APecipitation of FLAG-tagged 11E6 and 16E6 co-precipitates E6AP. The indicated
tion, protein equalized NP40 soluble lysates prepared and either analyzed by
cted to indicated epitope tags (Flag or EE) as previously described (Cooper et al.,
-16E6, or FLAG-11E6. Awhite vertical line between lanes 1 and 2 indicates the
ecipitates 11E6 and 16E6. Performed as in panel A. Black vertical lines group
uction of E6AP expression by co-expression of 11E6 and 16E6. The indicated
ount of beta-galactosidase included as an internal expression control. Protein
E tag on E6AP, then beta-galactosidase, then cellular tubulin as a loading control
fail to interact with E6AP. In two parallel sets of transfections either EE-E6AP or
wild-type (WT) or the indicated 11E6 mutants. Mutant C66G/C137G are in the
s undetermined in location in a recent structural model of E6 proteins (Nomine et
alyzed for expression in the upper three panels. Cells transfected with EE-E6AP-
on analyzed for EE-E6AP-C843A and tubulin expression in the lysate and the
ed with the indicated antibodies. (E) 11E6 and 16E6 associate with E6AP when
G-tagged vector, 16E6, 11E6 or the indicated 11E6 mutants. 5% of clarified and
ter completion of drug selection were analyzed by immunoblot for the expression
he remaining lysate was immune precipitated with rabbit polyclonal antibody to
6 and associated E6AP using mouse monoclonal antibodies to FLAG and E6AP.
305N. Brimer et al. / Virology 358 (2007) 303–310(E6AP-C843A) enhanced the yield of the co-immune precipi-
tated products. Mutation of the LQELL E6-binding motif of
E6AP to LQELS caused a partial reduction, and further mutation
to LQEAS caused a full loss of co-immune precipitation for both
11E6 and 16E6 (Figs. 2A and B). The association of untagged
11E6 with E6AP was also observed by transient co-expression
of the two proteins, purification of E6AP and visualization of
both proteins by silver stained gels.16E6 co-expression with E6AP has been shown to reduce
expression levels of E6AP (Kao et al., 2000). We observed this
with 11E6 as well, and it required an intact LQELL motif on
E6AP, as mutation of LQELL to LQELS caused a slight
restoration of E6AP levels and further mutation to LQEAS a
complete restoration of co-expressed E6AP levels (Fig. 2B).
Mucosal papillomavirus E6 types 11 and 16 were able upon co-
expression to decrease levels of E6AP while E6 proteins from
Fig. 3. E6AP association with 16E6 and 11E6 in cellular lysates. CBD-TEV-
FLAG fusions to 16E6, 16E6_Y79N, 11E6, and 1E6 were produced in CV1
cells by vaccinia virus transduction, bound to chitin beads and combined with
clarified HaCat cell lysate as described in the methods. FLAG-E6 and associated
proteins were released from chitin beads by TEV protease cleavage, and then
purified on FLAG antibody beads, washed extensively, eluted by FLAG peptide.
(A) Association of E6AP with 16E6. Black dots indicate silver-stained bands
excised from a 4–20% gradient polyacrylamide gel for protein identification by
in-gel trypsinization and LC-MS identification of tryptic peptides. Thirty-one
unique peptides in the indicated 100 kDa band in the 16E6 lane were derived
from E6AP, while no E6AP peptides were identified in the corresponding gel
slice for 16E6_Y79N. Molecular weight markers (lane 1) contain 100 ng protein
per band. (B) Association of E6AP with 11E6. In vitro binding and in-gel
trypsinization performed as in panel A. The indicated 100 kDa band in lane 3
contained 60 unique peptides derived from E6AP.
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Expression of co-transfected beta-galactosidase was not
similarly affected by the expression of E6 proteins (Fig. 2C).
11E6 is necessary for the maintenance of normal copy
number of episomal HPV-11 genomes in transfected keratino-
cytes; that study also characterized a set of 11E6 mutants that
each failed to support normal plasmid copy number (Oh et al.,
2004). In order to determine if one or more of these 11E6
mutants were defective for association with E6AP or failed to
reduce co-expressed E6AP levels, epitope-tagged 11E6 and the
11E6 mutants were co-expressed with E6AP-C843A (mutated
in ubiquitin ligase activity) and analyzed for association by
immune precipitation with antibodies directed against the E6
tags as illustrated in Fig. 2D. 11E6 mutants that fail to support
HPV-11 episomal copy number failed to co-precipitate with
E6AP-C843A (Fig. 2D lower panel), and failed to induce the
loss of co-expressed E6AP after transient expression (Fig. 2D
upper panel). Experiments 2A through D all utilized transient
overexpression. In order to determine if 11E6 was associated
with endogenous E6AP under stable expression conditions, 2X-
FLAG epitope-tagged 16E6, 11E6, and the 11E6 mutants used
in Fig. 2D were introduced into HPV-negative C33A cervical
cancer cells by retroviral transduction, pooled drug-resistant
colonies were grown to confluency, and passaged in 1:5
dilutions ten times. Protein-equalized NP40 cell lysates from
6×107 cells of each cell line were immune precipitated with
antibody to FLAG and analyzed for associated endogenous
E6AP. Both FLAG-tagged 16E6 and 11E6 were found to be
associated with E6AP while none of the 11E6 mutants that are
defective for stable HPV-11 plasmid maintenance were
associated with E6AP (Fig. 2E).
E6AP may interact with 11E6 by sensitive immunoblot
assays, yet not be a major interacting cellular protein with 11E6.
Further, the ability of 16E6 and 11E6 to induce the loss of E6AP
when co-expressed might distort the association pattern of E6
with cellular proteins isolated from in vivo co-expression. In
order to determine if E6AP is a principle interaction target with
11E6, a tandem affinity purification tag (chitin-binding domain
fused to a TEV protease site and FLAG epitope tag) was fused
to the amino-terminus of either 16E6, 16E6_Y79N (the Y79N
mutant is decreased for interaction with E6AP (Cooper et al.,
2003)), or 11E6 and expressed in CV1 cells. CBD-TEV-FLAG-
E6 fusions in the clarified soluble cell fraction were bound to
chitin beads which were recovered by centrifugation but were
not washed with detergent containing buffers, and those beads
were then added to excess clarified lysate from HaCat cells.
After incubation, the chitin beads were recovered, washed with
NP40-containing lysis buffer and E6 and any associated
proteins were released from the beads by TEV protease
cleavage followed by affinity capture with FLAG antibody
beads and elution by FLAG peptide. A silver stained gel shows
16E6 and associated products with identifications determined
by mass spectrometry (Fig. 3A). Candidate E6AP bands (silver
stained bands between 90 to 100 kDa) were excised and the
proteins identified by mass spectrometry. A distinct 16E6-
associated band at 100 kDa was identified as E6AP that was not
retained by 16E6_Y79N, demonstrating that by this assay,E6AP is a major interacting protein with 16E6, as expected, and
that the Y79N mutation that is defective for association with
E6AP lost association in this assay. A parallel binding assay
using 11E6 and 1E6 fusions demonstrated E6AP as a major
associated protein for 11E6 but a co-migrating band was not
observed with 1E6 (Fig. 3B). This demonstrates that E6AP is
preferentially captured by 11E6 from unfractionated cell lysate
in a similar fashion as by 16E6.
E6AP was discovered as an essential cellular co-factor for
the targeted degradation of p53 by 16E6 (Huibregtse et al.,
1991; Scheffner et al., 1990). Studies have documented that
11E6 fails to associate with (Werness et al., 1990) or target the
degradation of p53 (Scheffner et al., 1990), and as yet cellular
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11E6 have not yet been identified. However, it was shown that
11E6 could target the degradation of DLG1 in vitro if a seven
amino acid PDZ ligand derived from HPV-18 E6 was fused to
the carboxy-terminus of 11E6 (this 11E6 mutant is termed here
11.18E6) (Pim et al., 2002). In order to determine if E6AP can
provide the ubiquitin ligase activity in that assay, E6AP null
fibroblasts were co-transfected with EE-tagged DLG1, various
E6 genes (FLAG-tagged 11E6, PDZ-ligand-tagged 11E6
(ll.18E6) or 18E6), and wild-type E6AP or E6AP-C843A
(Fig. 4). Wild-type 11E6 did not significantly alter the
expression levels of DLG1 regardless of co-expressed E6AP
or the presence of proteasome inhibitor MG132. In contrast,
18E6 reduced the expression levels of DLG1 only in the
presence of co-expressed E6AP (and not E6AP-C843A), and
this was largely abrogated by the addition of proteasome
inhibitor MG132. This indicates that in fibroblasts, the
degradation of DLG1 by 18E6 is dependent upon both E6AP
and the proteasome. 11E6 with a PDZ ligand from 18E6 fused
to the carboxy-terminus of 11E6 performed similar to 18E6 in
that the loss of DLG1 expression was only observed with
E6AP (and not with E6AP-C843A) and was reversed by
proteasome inhibition (Fig. 4). Expression levels of transfected
E6AP were low in this assay and difficult to detect by
immunoblot. While both full-length FLAG-18E6 as well as a
presumed spliced and truncated FLAG-18E6* product were
observed, only FLAG-11E6 migrating at the expected full-
length size was observed.Fig. 4. E6AP and proteasome-dependent degradation of a synthetic substrate by
11E6. E6AP null mouse embryo fibroblasts were transfected with the indicated
plasmids. SDS lysed cells were analyzed by immunoblot 24 h later. Black
vertical lines group together samples transfected either with FLAG vector,
FLAG-11E6, or FLAG-11.18E6 (11E6 with a c-terminal fusion to the 7 amino
acid PDZ ligand of 18E6). FLAG-18E6 transfected cells produced two species
corresponding to the expected 20 kDa full-length FLAG-18E6 and a smaller
indicated band that is presumed to result from an internally spliced 18E6 product
termed 18E6*. A constant amount of luciferase was included in the transfection
mixture in lanes 2–9 as a transfection efficiency control.Discussion
Our experiments demonstrate that 11E6, like 16E6, associ-
ates with E6AP. The association depends upon an intact
LXXLL motif on E6AP (E6AP aa. 408-TLQELLGE-415), and
this association can result in the reduction of co-expressed
E6AP protein levels and degradation of an 11E6-associated
protein (the synthetic interaction of DLG1 with 11.18E6).
Bacterially expressed and purified 16E6 directly interacts with
LQELL peptides, but this has not been demonstrated in this
study, so the possibility remains that an additional cellular
protein could function as an adapter, coupling 11E6 to the
LQELL motif of E6AP indirectly.
Despite the similarity between 11E6 and 16E6 in interaction
with E6AP, several differences were noted. One difference
between 11E6 and 16E6 was seen in the ability of 16E6 to
interact with the isolated LQELL peptide in yeast, which was
not observed with 11E6. In further experiments not shown
here, we have observed that 16E6 overexpressed in one cell
lysate interacts with E6AP readily when mixed with E6AP
expressed in a different cell lysate, but that 11E6 associated less
efficiently under these conditions, and was much more
efficiently associated with E6AP when co-expressed with
E6AP. Further, GST or CBD fusions to 11E6 prepared in
bacteria and purified and washed in the presence of non-ionic
detergents failed to interact with E6AP at all (our unpublished
observations). This may account for the failure of previous
studies to identify E6AP or its LQELL peptide as a principle
interacting protein with low-risk E6 proteins (Elbel et al., 1997;
Zanier et al., 2005).
Previous studies had demonstrated that the expression of
16E6 reduced co-expressed E6AP (Talis et al., 1998). We
observed the same result for 11E6 (Figs. 2B, C, D, and 4). In
addition, mutants of 11E6 that in a previous study failed to
support the stable plasmid replication of HPV-11 when
expressed in the full context of the HPV genome also in our
studies failed to either associate with E6AP or target the
degradation of E6AP, despite similar or greater levels of
expression (Figs. 2D and E). This supports the biological
significance of the association of 11E6 with E6AP.
E6AP participates in the targeted degradation of both p53
and cellular PDZ proteins when associated with high-risk E6
proteins such as 16E6 or 18E6. Using a chimera of 11E6 with
the PDZ ligand of 18E6, we observed the targeted degradation
of DLG1 in an E6AP and proteasome-dependent manner,
similar to a parallel experiment using 18E6. Thus, 11E6
association with E6AP resulted in the proteasome-dependent
degradation of an additional associated protein. Our result with
18E6 is in contrast to earlier studies using in vitro degradation
assays of DLG1 by 18E6, in which depletion of E6AP from
reticulocyte lysate by immune precipitation, or inhibition of
degradation by various peptide competitors ablated the
degradation of p53 but not DLG1. This result prompted the
authors to postulate the presence of an additional ubiquitin
ligase (not E6AP) that when associated with 18E6 targeted the
degradation of DLG1(Grm and Banks, 2004; Sterlinko Grm et
al., 2004). Given the differing sensitivity of substrates to in
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have uncertainties if residual E6AP is present. Our genetic
results do not completely eliminate the possibility of an
alternative ubiquitin ligase to E6AP that is present in
reticulocyte lysate but not evident in fibroblasts. However,
our results demonstrate that E6AP can provide a ubiquitin
ligase activity to target the degradation of DLG1 by 18E6, and
that E6AP null fibroblasts do not express sufficient amounts of
an alternative ubiquitin ligase to be apparent in this assay.
We demonstrated that E6AP is a principle binding partner of
both 11E6 and 16E6 in vitro (Fig. 3). This resulted from
competitive binding of total cell lysate to the E6 proteins. Given
that E6AP is not an abundant protein, this argues that E6AP is a
principle associated protein for both high- and low-risk E6
proteins.
This study has not yet identified authentic cellular
substrates, if any, that are targeted for degradation by 11E6
together with E6AP, which is the topic of ongoing investiga-
tions. It may be that such substrates were not present in the
soluble HaCat cell lysate used in Fig. 3. Alternatively,
formation of a ternary complex between 11E6, E6AP and a
putative cellular protein degradation target may be an active
process, unlike with 16E6 where interaction with E6AP and
p53 occurs in vitro (Huibregtse et al., 1993b). It is also possible
that the 11E6-E6AP complex has a primary role besides the
targeted degradation of particular cellular proteins. It is
important to note that although we have shown that 11E6
together with E6AP have the capacity to target an associated
protein for degradation, there is no evidence that this occurs in
the viral life cycle. The concept that 11E6 targets an additional
cellular protein for degradation, like 16E6, is at this point an
attractive assumption for which there is as yet no clear
evidence. It has been proposed that E6AP acts as a transcription
factor coactivator for steroid receptors (Nawaz et al., 1999),
and association with 11E6 might modulate the role of E6AP as
a coactivator. For its proposed role as a steroid receptor family
co-activator, the ubiquitin ligase activity was found to be
dispensable, indicating E6AP has functions that are not
dependent upon the ubiquitin ligase activity, and that the
ubiquitin ligase defective mutant used in this study (E6AP-
C843A) is not globally defective (Nawaz et al., 1999). Inde-
pendent investigations of E6AP as a transcription co-activator
of the telomerase promoter have not as yet defined the role of
the ubiquitin ligase function of E6AP for E6 transactivation of
the telomerase promoter (Liu et al., 2005). A recent study has
also demonstrated RNAi-mediated knockdown of either high-
risk E6 or E6AP in HPV-positive cervical cancer cell lines had
very similar effects upon the transcriptional profile of the cells,
indicating that alterations in transcription by high-risk E6
proteins are predominantly mediated by E6AP in some way
(Kelley et al., 2005).
The common association of E6 proteins from both high-risk
and low-risk mucosal papillomavirus types with E6AP is a
significant if not surprising observation. Given the prevalence
and morbidity associated with mucosal papillomavirus infec-
tions, modulation of either E6AP function or the E6-E6AP
interaction is an attractive target for anti-papillomavirustherapeutics for both cancerous and non-cancerous tumors.
Recent experiments have demonstrated that RNAi-mediated
decrease of E6AP expression in cervical cancer cell lines results
in growth suppression and elevation of p53 expression
(Hengstermann et al., 2005). Further studies of the association
of low-risk E6 proteins with E6AP may reveal a possible role of
E6AP in the full virus life cycle.
Materials and methods
Cells and tissue culture
CV-1 and HaCat cells were maintained in DMEM media
supplemented with 10% newborn calf serum, glutamine and
antibiotics. E6AP null mouse fibroblasts are derived from
primary mouse embryo fibroblasts deleted in both Ube3a
(E6AP) genes and are spontaneously immortalized (Jiang et
al., 1998). Ube3A null fibroblasts were transfected by
Lipofectamine 2000 (Invitrogen) in accordance with the
manufacturer's instructions, and transient Vaccinia virus
expression of proteins was performed in CV-1 cells as described
(Elroy-Stein et al., 1989).
Plasmids
Human E6AP and E6AP-C843A-(mutated in ubiquitin
ligase activity) cDNAs were provided by John Huibregtse
(University of Texas, Austin) and are numbered in accordance
to Genbank Q05086. E6AP mutants in the E6-binding motif
were created by oligonucleotide directed mutagenesis and were
fully sequenced and were without polymerase-generated errors.
11E6 with a fusion to the PDZ domain of 18E6 was recreated as
described (Pim et al., 2002). Epitope-tagged plasmids used in
mammalian transfection were created in pcDNA3, and
retroviral transductions were performed as previously described
(Bohl et al., 2000).
Yeast two-hybrid assay
The TAT7 strain of yeast was a gift of R. Sternglanz and
contains lexA responsive lacZ and His3 reporter genes, and is
MATa and is leu2, ade2, and trp1. YPH 500 is mat alpha, ura 3-
52, ly2-801, ade2-101, trp1-Δ63, his3-Δ200, leu2Δ1, and is
used to introduce plasmids by mating with TAT7. Empty
expression plasmids containing appropriate selection markers
were introduced into mating strains so that for any particular
experiment all selected yeast contained the same number of
plasmid types and expressed the same auxotrophic phenotypes.
Yeast mating, selection and transfection were as previously
described (Vande Pol et al., 1998). The yeast prey plasmids
expressing E6AP, E6AP-C843A fused to the B42 transactiva-
tion domain and prey plasmids expressing the E6-binding
motifs of E6AP (the isolated E6AP E6-binding motif (amino
acids 407–418, LQELL)), or mutated peptide from E6AP
(amino acids 407–418, LQELS) been previously described
(Cooper et al., 2003), and are separated from the B42
transactivation domain by the hemagglutinin HA epitope.
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The CBD-TEV-FLAG purification cassette (chitin-binding
domain in frame fused to a TEV (tobacco etch virus protease)
cleavage site followed by a FLAG antibody epitope tag) was
fused in frame to either 16E6, 16E6_Y79N 11E6, or 1E6 was
expressed in confluent monkey CV1 cells by lipofection and
T7 polymerase directed expression using the T7-expresssing
vaccinia virus Vtf-7 (Elroy-Stein et al., 1989). 24 h after
infection, media was removed, cells washed three times with
ice-cold PBS, and lysed on ice with 0.5× NP40 lysis buffer (1×
NP40 lysis buffer contains150 mM NaCl; 50 mM Tris pH 7.5;
50 mM NaF; 5 mM NaPPi; 1% IGEPAL; 0.01% phenyl-
methylsulfonyl fluoride; 5 mM EDTA; 1 mM sodium vanadate;
1 μg/ml leupeptin/aprotinin). Lysates were centrifuged at
15000× g at 4 °C for 10 min. Clarified lysates from
approximately 1×107 CV1 cells were incubated with 25 μl
chitin beads for 30 min with rocking at 4 °C. The chitin beads
were recovered by centrifugation and the cell lysate was remove
and replaced by cell lysate from 2×108 HaCat cells lysed in
5 ml 0.5× NP40 lysis buffer, and incubated with rotation at
4 °C for 1 h. The beads were recovered by centrifugation, and
washed 4 times with 1× NP40 lysis buffer and twice by TEV
protease cleavage buffer, followed by cleavage of E6 from the
beads with 1 U TEV according to the manufacturer's
instructions (Invitrogen). The beads were discarded and the
supernatant for the TEV cleavage reaction was applied to 20 μg
FLAG M2 antibody covalently immobilized on agarose beads
for 1 h at 4 °C. The FLAG beads were washed three times with
NP40 lysis buffer, twice with 0.25× NP40 lysis buffer and
FLAG-E6 with associated proteins were eluted by three rounds
of elution with 2 μg FLAG peptide in 25 μl 0.25× NP40 buffer.
Eluates were combined, frozen, lyophilized, and resuspended
in SDS PAGE sample buffer and applied to 4–20% Novex
polyacrylamide gels. Gels were stained with silver to visualize
protein bands. The gel bands were subsequently cut from the
gel and destained. The proteins were reduced, alkylated and
digested with trypsin in the gel. The peptides formed in the
digestion were extracted, concentrated, and characterized by
capillary column LC-tandem MS. Database searches were
performed using the program SEQUEST.Western blot analysis
0.5× NP40 cell lysates were equalized for protein content as
determined with a commercial kit (Bio-Rad) before electropho-
resis; equalized proteins boiled in complete SDS sample buffer
were resolved by SDS-PAGE electrophoresis and transferred to
PVDF membranes and ponceau stained. Antibody sources:
epitope tags were obtained from Sigma Chemicals (M2 FLAG
and rabbit polyclonal against the FLAG epitope), Covance
(rabbit polyclonal anti-EE epitope), beta-galactosidase (Pro-
mega, monoclonal), E6AP (monoclonal, BD Biosystems) and
tubulin (Sigma mouse monoclonal). Immune precipitations
with FLAG antibody used FLAG-M2 covalently coupled to
agarose beads (Sigma).Acknowledgments
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